Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(4.71)
# 314
Out of 5,182 analysts
32
Total ratings
69.57%
Success rate
33.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCAX Bicara Therapeutics | Maintains: Equal-Weight | $11 → $16 | $22.14 | -27.73% | 4 | Mar 31, 2026 | |
| NUVL Nuvalent | Initiates: Overweight | $116 | $103.69 | +11.87% | 1 | Mar 30, 2026 | |
| STRO Sutro Biopharma | Upgrades: Overweight | $8 → $27 | $26.19 | +3.09% | 1 | Mar 24, 2026 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $15 → $17 | $15.26 | +11.40% | 4 | Mar 17, 2026 | |
| GMAB Genmab | Initiates: Overweight | $40 | $28.20 | +41.84% | 1 | Mar 2, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $100 → $144 | $136.30 | +5.65% | 2 | Feb 26, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Overweight | $50 → $53 | $47.30 | +12.05% | 4 | Feb 25, 2026 | |
| RCUS Arcus Biosciences | Downgrades: Equal-Weight | $30 → $23 | $22.39 | +2.72% | 5 | Feb 12, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $30 → $35 | $44.96 | -22.15% | 1 | Feb 11, 2026 | |
| ZYME Zymeworks | Upgrades: Overweight | $25 → $33 | $26.17 | +26.10% | 4 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $31.47 | +90.66% | 1 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $27 | $12.07 | +123.70% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $32.82 | +34.06% | 1 | Jun 26, 2025 |
Bicara Therapeutics
Mar 31, 2026
Maintains: Equal-Weight
Price Target: $11 → $16
Current: $22.14
Upside: -27.73%
Nuvalent
Mar 30, 2026
Initiates: Overweight
Price Target: $116
Current: $103.69
Upside: +11.87%
Sutro Biopharma
Mar 24, 2026
Upgrades: Overweight
Price Target: $8 → $27
Current: $26.19
Upside: +3.09%
Relay Therapeutics
Mar 17, 2026
Maintains: Overweight
Price Target: $15 → $17
Current: $15.26
Upside: +11.40%
Genmab
Mar 2, 2026
Initiates: Overweight
Price Target: $40
Current: $28.20
Upside: +41.84%
Revolution Medicines
Feb 26, 2026
Maintains: Overweight
Price Target: $100 → $144
Current: $136.30
Upside: +5.65%
Kiniksa Pharmaceuticals International,
Feb 25, 2026
Maintains: Overweight
Price Target: $50 → $53
Current: $47.30
Upside: +12.05%
Arcus Biosciences
Feb 12, 2026
Downgrades: Equal-Weight
Price Target: $30 → $23
Current: $22.39
Upside: +2.72%
Exelixis
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $30 → $35
Current: $44.96
Upside: -22.15%
Zymeworks
Dec 12, 2025
Upgrades: Overweight
Price Target: $25 → $33
Current: $26.17
Upside: +26.10%
Oct 31, 2025
Initiates: Overweight
Price Target: $60
Current: $31.47
Upside: +90.66%
Aug 7, 2025
Maintains: Overweight
Price Target: $33 → $27
Current: $12.07
Upside: +123.70%
Jun 26, 2025
Initiates: Overweight
Price Target: $44
Current: $32.82
Upside: +34.06%